The period in brief
- Net asset value was SEK 3,947 million (3,416) and net asset value per share was SEK 50.56 (56.24), adjusted net asset value per share was 51.88 (56.24). Change in net asset value per share in the quarter was -6.0 per cent (-4.2).
- Total fair value of shares in portfolio companies was SEK 2,874 million (2,831). Change in fair value of shares in portfolio companies was SEK -197 million (-153), equivalent to -6.4 per cent (-5.5).
- Net profit/loss amounted to SEK -251 million (-150)
- Earnings per share before and after dilution amounted to SEK -3.22 (-2.46)
Significant events during the quarter
- The value of the investment in the US-based portfolio company Provell Pharmaceuticals was fully written-down following the discontinuing of a significant distribution contract, resulting in a financial cost of SEK 82 million.
- Flerie announced the divestment of all shares in the portfolio company A3P Biomedical for a total consideration of SEK 71 million, representing a valuation 55 per cent above the latest fair value reported.
- On 25 March 2025, Flerie and Toleranzia jointly announced that the respective Boards had adopted a plan to join forces through a merger between the two companies. The Merger will be implemented by Toleranzia being absorbed by Flerie, and is conditional upon approvals at General Meetings in both Companies.
- Investments in shares in portfolio companies were SEK 48 million.
Flerie will host a live presentation today, Wednesday April 16, at 11:00 CEST. The call will be hosted by Ted Fjällman (CEO) and Cecilia Stureborg von Schéele (CFO). The presentation will be held in English and include a Q&A session.
If you wish to participate via webcast please register via the link below. Please note that it can take a few minutes to receive the confirmation e-mail with the Teams link following registration.
https://events.teams.microsoft.com/event/ec031c70-3bc5-490f-84a7-649aad0142a5@8a6f565d-42e1-4b27-93d3-51ae5cf1e4a2
The presentation will be available after the webcast at www.flerie.com.
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com
This information is information that Flerie AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-16 08:00 CEST.
